Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013

Mary Gleeson, FRCPath, Eliza A Hawkes, MD, Clare Peckitt, MSc, Andrew Wotherspoon, FRCPath, Ayoma Attygalle, PhD, Bhupinder Sharma, MD, Yong Du, MD, Mark Ethell, MD, Michael Potter, PhD, Claire Dearden, MD, Alan Horwich, MD, Ian Chau, MD, David Cunningham, FMedSci

Blood (2014) 124 (21): 1719.

https://doi.org/10.1182/blood.V124.21.1719.1719

Published: 2014

Journal Articles

Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [ 18 f]FDG-PET Prior to Allogeneic Transplant

Robert N Lown, MBBS, MDRes), MRCP, FRCPath, Anastasia Constantinidou, Caroline Ebdon, Kabir Mohammed, Mark Ethell, MD, Ian Chau, MD, David Cunningham, FMedSci, Michael Potter, PhD, Bhupinder Sharma, MD

Blood (2014) 124 (21): 1249.

https://doi.org/10.1182/blood.V124.21.1249.1249

Published: 2014

Journal Articles

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

Hervé Dombret, MD PhD, Claude Preudhomme, MD PhD, Céline Berthon, MD, Emmanuel Raffoux, MD, Xavier Thomas, MD PhD, Norbert Vey, MDPhD, Carlos Gomez-Roca, MD, Mark Ethell, MD, Karen Yee, MD, Fabrice Bourdel, MSc, Patrice Herait, MD PhD, Mauricette Michallet, MD PhD, Christian Recher, MDPhD, Christophe Roumier, Bruno Quesnel, MD

Blood (2014) 124 (21): 117.

https://doi.org/10.1182/blood.V124.21.117.117

Published: 2014

Journal Articles

High Rates of Passive CMV Antibody Acquisition Pre-Allograft in Patients Receiving Plasma-Rich CMV Unselected and Leukodepleted Blood Components: A Caution for Donor Selection

Robert N Lown, MBBS, MDRes), MRCP, FRCPath, Unell Riley, Mark Ethell, MD, Michael N Potter, MD PhD

Blood (2014) 124 (21): 1140.

https://doi.org/10.1182/blood.V124.21.1140.1140

Published: 2014

Journal Articles

Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma

Blood (2014) 124 (21): 3971.

https://doi.org/10.1182/blood.V124.21.3971.3971

Published: 2014

Journal Articles

Results of a Prospective Clinical Trial of Pre-DLI Lymphoreduction Using Oral Fludarabine In Patients with Mixed Chimerism Post Allogeneic Transplant.

Bronwen E. Shaw, PhD, MRCP, FRCPath, Jenny Byrne, MD, PhD, Emma Das-Gupta, DM, FRCPath, MRCP, Mark Ethell, MA, MBBChir, MRCP, FRCPath, Daniel Figueroa, J. Alejandro Madrigal, MD, PhD, Gareth J Morgan, MD, PhD, Sameer Tulpule, MBBS, MD, MRCP, Michael Potter, MA, MB, Phd, FRCP, (UK), FRCPath, Nigel H. Russell, MD

Blood (2010) 116 (21): 1299.

https://doi.org/10.1182/blood.V116.21.1299.1299

Published: 2010

Journal Articles

Maintenance Chemotherapy (MC) after Autotransplantation in First-Remission Acute Lymphoblastic Leukemia (ALL): Single-Center Experience of 100 Patients.

Bhawna Sirohi, Ray Powles, Jennifer Treleaven, Samar Kulkarni, Radovan Saso, Mike Potter, Mark Ethell, Gareth Morgan, Seema Singhal, Jayesh Mehta

Blood (2007) 110 (11): 2874.

https://doi.org/10.1182/blood.V110.11.2874.2874

Published: 2007

Journal Articles

Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant.

Samar Kulkarni, MRCP, Michael Potter, MRCPath, Mark Ethell, PRCPath, Radovan Saso, PhD, Jennifer Treleaven, FRCPath, Joy Brennan, BSc, Pawel Kaczmarek, MRCP, Prashant Hiwarkar, MRCP, Pamala Kanagasabapathy, MRCP, Caroline Alvares, MRCPath, Clive Horton, PhD, Raymond Powles, FRCP, Frank Saran, FRCR, Gareth Morgan, FRCPath

Blood (2006) 108 (11): 551.

https://doi.org/10.1182/blood.V108.11.551.551

Published: 2006

Journal Articles

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation.

Caroline Alvares, MRCPath, Samar Kulkarni, MRCP, Pawel Kaczmarek, PhD, Radovan Saso, PhD, Helena Woods, Joy Brennan, BSc, Clive Horton, PhD, Jennifer Treleaven, FRCPath, Mark Ethell, MRCPath, Claire Dearden, MRCPath, Gareth Morgan, FRCPath, Michael Potter, FRCPath

Blood (2006) 108 (11): 5324.

https://doi.org/10.1182/blood.V108.11.5324.5324

Published: 2006

Journal Articles

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care.

Girish Ravindranathan, MRCP, Vaia Grigoriadou, MRCP, Radovan Saso, MD, PhD, Shelley Dolan, MSc, PhD, Mark Ethell, MRCP, MRCPath, Michael Potter, FRCP, FRCPath, Jennifer Treleaven, FRCP, FRCPath, Gareth Morgan, FRCP, FRCPath

Blood (2006) 108 (11): 5289.

https://doi.org/10.1182/blood.V108.11.5289.5289

Published: 2006

Journal Articles

Pregnancy Outcome Following Haematopoietic Stem Cell Transplantation.

Samar Kulkarni, MRCP, Mark Ethell, MRCPath, Jennifer Treleaven, FRCPath, Radovan Saso, PhD, Joy Brennan, BsC, Pawel Kaczmarek, PhD, Caroline Alvares, MRCPATH, Clive Horton, PhD, Frank Saran, FRCR, Pamala Kanagasabapathy, MRCP, Prashant Hiwarkar, MRCP, Stella Appiah-Cubi, MRCP, Moez Dungarwala, MRCP, Raymond Powles, FRCP, Gareth Morgan, FRCPath, Michael Potter, FRCPath

Blood (2006) 108 (11): 3367.

https://doi.org/10.1182/blood.V108.11.3367.3367

Published: 2006

Journal Articles

A Comparative Analysis of Outcomes in Primary Myelodysplastic Syndrome (MDS) and Therapy-Related MDS Reveals Two Subgroups with Differing Risk Profiles: Implications for the Application of a Prognostic Classification.

Caroline Alvares, Sue Ashley, Radovan Saso, Gita Patel, Amrana Qureshi, Michael Potter, Mark Ethell, Jennifer Treleaven, Claire Dearden, Gareth Morgan

Blood (2005) 106 (11): 2532.

https://doi.org/10.1182/blood.V106.11.2532.2532

Published: 2005

Journal Articles

Responses to Induction Chemotherapy and High Dose Melphalan Can Be Incorporated within a Risk Stratification Model and Help to Identify Myeloma Patients Who May Benefit from Novel Therapies.

Caroline L. Alvares, Faith E. Davies, Clive Horton, Gita Patel, Roslin Zuha, Alex Gatt, Radovan Saso, Jennifer Treleaven, Mark Ethell, Mike Potter, Claire Dearden, Gareth J. Morgan

Blood (2004) 104 (11): 2394.

https://doi.org/10.1182/blood.V104.11.2394.2394

Published: 2004

Journal Articles

Pathologic Features May Predict the Clinical Outcome of Hepatic Graft Versus Host Disease (H-GVHD).

Rafael F. Duarte, Julio Delgado-Gonzalez, Bronwen E. Shaw, David Wrench, Mark Ethell, David Patch, Amar P. Dhillon, Stephen Mackinnon, Michael Potter, Alberto F. Quaglia

Blood (2004) 104 (11): 5079.

https://doi.org/10.1182/blood.V104.11.5079.5079

Published: 2004

Journal Articles

Recipient CMV Seropositivity Predicts Relapse Post Allogeneic Transplantation in Children.

Roslin Zuha, MRCP, MRCPATH, Alex Gatt, MRCP, MRCPATH, Caroline Alvares, MRCP, MRCPATH, Clive Horton, Gita Patel, Mark Ethell, MRCP, MRCPATH, Michael Potter, FRCP, FRCPATH

Blood (2004) 104 (11): 5140.

https://doi.org/10.1182/blood.V104.11.5140.5140

Published: 2004

NARROW

Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013

Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [ 18 f]FDG-PET Prior to Allogeneic Transplant

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

High Rates of Passive CMV Antibody Acquisition Pre-Allograft in Patients Receiving Plasma-Rich CMV Unselected and Leukodepleted Blood Components: A Caution for Donor Selection

Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma

Results of a Prospective Clinical Trial of Pre-DLI Lymphoreduction Using Oral Fludarabine In Patients with Mixed Chimerism Post Allogeneic Transplant.

Maintenance Chemotherapy (MC) after Autotransplantation in First-Remission Acute Lymphoblastic Leukemia (ALL): Single-Center Experience of 100 Patients.

Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant.

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation.

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care.

Pregnancy Outcome Following Haematopoietic Stem Cell Transplantation.

A Comparative Analysis of Outcomes in Primary Myelodysplastic Syndrome (MDS) and Therapy-Related MDS Reveals Two Subgroups with Differing Risk Profiles: Implications for the Application of a Prognostic Classification.

Responses to Induction Chemotherapy and High Dose Melphalan Can Be Incorporated within a Risk Stratification Model and Help to Identify Myeloma Patients Who May Benefit from Novel Therapies.

Pathologic Features May Predict the Clinical Outcome of Hepatic Graft Versus Host Disease (H-GVHD).

Recipient CMV Seropositivity Predicts Relapse Post Allogeneic Transplantation in Children.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only